One of the CBD companies targeted in an unusual recent round of US Food and Drug Administration (FDA) warning letters has told CannIntelligence it is hopeful that the 2023 Farm Bill will finally enable US regulators to create a legitimate path to market for CBD-containing ingestible products.
CBDfx received a warning letter from the FDA that emphasised the brand was “illegally selling products containing cannabidiol”.
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
LATEST ALERTS
